[1]

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, et al. 2021. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians 71:209−249

doi: 10.3322/caac.21660
[2]

Chen W, Zheng R, Baade PD, Zhang S, Zeng H, et al. 2016. Cancer statistics in China, 2015. CA: A Cancer Journal for Clinicians 66:115−132

doi: 10.3322/caac.21338
[3]

Bonelli P, Borrelli A, Tuccillo FM, Silvestro L, Palaia R, et al. 2019. Precision medicine in gastric cancer. World Journal of Gastrointestinal Oncology 11:804−829

doi: 10.4251/wjgo.v11.i10.804
[4]

Sasayama D, Hori H, Yamamoto N, Nakamura S, Teraishi T, et al. 2014. ITIH3 polymorphism may confer susceptibility to psychiatric disorders by altering the expression levels of GLT8D1. Journal of Psychiatric Research 50:79−83

doi: 10.1016/j.jpsychires.2013.12.002
[5]

Yang CP, Li X, Wu Y, Shen Q, Zeng Y, et al. 2018. Comprehensive integrative analyses identify GLT8D1 and CSNK2B as schizophrenia risk genes. Nature Communications 9:838

doi: 10.1038/s41467-018-03247-3
[6]

Cooper-Knock J, Moll T, Ramesh T, Castelli L, Beer A, et al. 2019. Mutations in the glycosyltransferase domain of GLT8D1 are associated with familial amyotrophic lateral sclerosis. Cell Reports 26:2298−2306.e5

doi: 10.1016/j.celrep.2019.02.006
[7]

Chan Moi Fat S, McCann EP, Williams KL, Henden L, Twine NA, et al. 2021. Genetic analysis of GLT8D1 and ARPP21 in Australian familial and sporadic amyotrophic lateral sclerosis. Neurobiology of Aging 101:297.e9−297.e11

doi: 10.1016/j.neurobiolaging.2021.01.005
[8]

Hu H, Li Z, Zhou Y, Zhang Y, Zhao L, et al. 2019. GLT8D1 overexpression as a novel prognostic biomarker in human cutaneous melanoma. Melanoma Research 29:612−620

doi: 10.1097/CMR.0000000000000631
[9]

Beddok A, Pérot G, Le Guellec S, Thebault N, Coutte A, et al. 2021. Germinal GLT8D1, GATAD2A and SLC25A39 mutations in a patient with a glomangiopericytal tumor and five different sarcomas over a 10-year period. Scientific Reports 11:9765

doi: 10.1038/s41598-021-88671-0
[10]

Ilina EI, Cialini C, Gerloff DL, Duarte Garcia-Escudero M, Jeanty C, et al. 2022. Enzymatic activity of glycosyltransferase GLT8D1 promotes human glioblastoma cell migration. iScience 25:103842

doi: 10.1016/j.isci.2022.103842
[11]

Hwang S, Mahadevan S, Qadir F, Hutchison IL, Costea DE, et al. 2013. Identification of FOXM1-induced epigenetic markers for head and neck squamous cell carcinomas. Cancer 119:4249−4258

doi: 10.1002/cncr.28354
[12]

Liu K, Jiang L, Shi Y, Liu B, He Y, et al. 2022. Hypoxia-induced GLT8D1 promotes glioma stem cell maintenance by inhibiting CD133 degradation through N-linked glycosylation. Cell Death & Differentiation 29:1834−1849

doi: 10.1038/s41418-022-00969-2
[13]

Pinho SS, Reis CA. 2015. Glycosylation in cancer: mechanisms and clinical implications. Nature Reviews Cancer 15:540−555

doi: 10.1038/nrc3982
[14]

Thomas D, Rathinavel AK, Radhakrishnan P. 2021. Altered glycosylation in cancer: a promising target for biomarkers and therapeutics. Biochimica et Biophysica Acta (BBA) − Reviews on Cancer 1875:188464

doi: 10.1016/j.bbcan.2020.188464
[15]

Taniguchi N, Kizuka Y. 2015. Glycans and cancer: role of N-glycans in cancer biomarker, progression and metastasis, and therapeutics. Advances in Cancer Research 126:11−51

doi: 10.1016/bs.acr.2014.11.001
[16]

Magalhães A, Duarte HO, Reis CA. 2021. The role of O-glycosylation in human disease. Molecular Aspects of Medicine 79:100964

doi: 10.1016/j.mam.2021.100964
[17]

Pinho SS, Carvalho S, Marcos-Pinto R, Magalhães A, Oliveira C, et al. 2013. Gastric cancer: adding glycosylation to the equation. Trends in Molecular Medicine 19:664−676

doi: 10.1016/j.molmed.2013.07.003
[18]

Goldman MJ, Craft B, Hastie M, Repečka K, McDade F, et al. 2020. Visualizing and interpreting cancer genomics data via the Xena platform. Nature Biotechnology 38:675−678

doi: 10.1038/s41587-020-0546-8
[19]

Chandrashekar DS, Bashel B, Balasubramanya SAH, Creighton CJ, Ponce-Rodriguez I, et al. 2017. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia 19:649−658

doi: 10.1016/j.neo.2017.05.002
[20]

Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, et al. 2019. STRING v11: protein – protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Research 47:D607−D613

doi: 10.1093/nar/gky1131
[21]

Franz M, Rodriguez H, Lopes C, Zuberi K, Montojo J, et al. 2018. GeneMANIA update 2018. Nucleic Acids Research 46:W60−W64

doi: 10.1093/nar/gky311
[22]

The Gene Ontology Consortium. 2015. Gene Ontology Consortium: going forward. Nucleic Acids Research 43:D1049−D1056

doi: 10.1093/nar/gku1179
[23]

Kanehisa M, Sato Y, Kawashima M, Furumichi M, Tanabe M. 2016. KEGG as a reference resource for gene and protein annotation. Nucleic Acids Research 44:D457−D462

doi: 10.1093/nar/gkv1070
[24]

Wu T, Hu E, Xu S, Chen M, Guo P, et al. 2021. clusterProfiler 4.0: a universal enrichment tool for interpreting omics data. The Innovation 2:100141

doi: 10.1016/j.xinn.2021.100141
[25]

Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, et al. 2005. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proceedings of the National Academy of Sciences of the United States of America 102:15545−15550

doi: 10.1073/pnas.0506580102
[26]

Hirano S. 2012. Western blot analysis. In Nanotoxicity: Methods in Molecular Biology, ed. Reineke J. Totowa, NJ: Humana. pp. 87−97 doi: 10.1007/978-1-62703-002-1_6
[27]

Cao M, Li H, Sun D, Chen W. 2020. Cancer burden of major cancers in China: a need for sustainable actions. Cancer Communications 40:205−210

doi: 10.1002/cac2.12025
[28]

Sexton RE, Al Hallak MN, Diab M, Azmi AS. 2020. Gastric cancer: a comprehensive review of current and future treatment strategies. Cancer and Metastasis Reviews 39:1179−1203

doi: 10.1007/s10555-020-09925-3
[29]

Silsirivanit A. 2019. Glycosylation markers in cancer. Advances in Clinical Chemistry 89:189−213

doi: 10.1016/bs.acc.2018.12.005
[30]

Nagae M, Yamaguchi Y, Taniguchi N, Kizuka Y. 2020. 3D structure and function of glycosyltransferases involved in N-glycan maturation. International Journal of Molecular Sciences 21:437

doi: 10.3390/ijms21020437
[31]

Ahmad Bhat S, Mir MUR, Majid S, Hassan T, Rehman MU, et al. 2018. Diagnostic utility of glycosyltransferase mRNA expression in gastric cancer. Hematology/Oncology and Stem Cell Therapy 11:158−168

doi: 10.1016/j.hemonc.2018.03.002
[32]

Dong S, Wang Z, Huang B, Zhang J, Ge Y, et al. 2017. Bioinformatics insight into glycosyltransferase gene expression in gastric cancer: POFUT1 is a potential biomarker. Biochemical and Biophysical Research Communications 483:171−177

doi: 10.1016/j.bbrc.2016.12.172
[33]

Guo H, Zhao L, Shi B, Bao J, Zheng D, et al. 2018. GALNT5 uaRNA promotes gastric cancer progression through its interaction with HSP90. Oncogene 37:4505−4517

doi: 10.1038/s41388-018-0266-4
[34]

Lee PC, Chen ST, Kuo TC, Lin TC, Lin MC, et al. 2020. C1GALT1 is associated with poor survival and promotes soluble Ephrin A1-mediated cell migration through activation of EPHA2 in gastric cancer. Oncogene 39:2724−2740

doi: 10.1038/s41388-020-1178-7
[35]

Xu Y, Gao Z, Hu R, Wang Y, Wang Y, et al. 2021. PD-L2 glycosylation promotes immune evasion and predicts anti-EGFR efficacy. Journal for Immunotherapy of Cancer 9:e002699

doi: 10.1136/jitc-2021-002699
[36]

Ip CKM, Ng PKS, Jeong KJ, Shao SH, Ju Z, et al. 2018. Neomorphic PDGFRA extracellular domain driver mutations are resistant to PDGFRA targeted therapies. Nature Communications 9:4583

doi: 10.1038/s41467-018-06949-w
[37]

Liu Q, Shi Z, Liu X, Xiao H. 2020. Correlation between the coexpression of zinc finger and SCAN domain-containing protein 31 and transcriptional activator with PDZ-binding motif and prognosis in hepatocellular carcinoma. Annals of Translational Medicine 8:1308

doi: 10.21037/atm-20-6373
[38]

Lin SR, Wen YC, Yeh HL, Jiang KC, Chen WH, et al. 2020. EGFR-upregulated LIFR promotes SUCLG2-dependent castration resistance and neuroendocrine differentiation of prostate cancer. Oncogene 39:6757−6775

doi: 10.1038/s41388-020-01468-9
[39]

Acevedo-Díaz A, Morales-Cabán BM, Zayas-Santiago A, Martínez-Montemayor MM, Suárez-Arroyo IJ. 2022. SCAMP3 regulates EGFR and promotes proliferation and migration of triple-negative breast cancer cells through the modulation of AKT, ERK, and STAT3 signaling pathways. Cancers (Basel) 14:2807

doi: 10.3390/cancers14112807
[40]

Li C, Zhang Z, Lv P, Zhan Y, Zhong Q. 2020. SCAMP3 promotes glioma proliferation and indicates unfavorable prognosis via multiple pathways. OncoTargets and Therapy 13:3677−3687

doi: 10.2147/OTT.S242462